PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
21325074-2	2011	Sunitinib, a potent inhibitor of RET, VEGF receptor (VEGFR)-1, VEGFR-2, VEGFR-3, and platelet-derived growth factor receptor (PDGFR)alpha/beta, has been reported as clinically effective in some patients with advanced MTC.	Sunitinib	0-9	ret proto-oncogene	Homo sapiens	33-36	
21325074-4	2011	EXPERIMENTAL DESIGN: Both in vitro and in vivo assays, using the human TT RET(C634W) MTC cell line, were done to assess the activity of sunitinib.	Sunitinib	136-145	ret proto-oncogene	Homo sapiens	74-77	
21325074-6	2011	RESULTS: Sunitinib displayed antiproliferative and antiangiogenic activities and inhibited RET autophosphorylation and activation of downstream signaling pathways.	Sunitinib	9-18	ret proto-oncogene	Homo sapiens	91-94